- Home
- HRMY vs OI Comparison
HRMY vs OI Comparison
Compare HRMY & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- OI
- Stock Information
- Founded
- HRMY 2017
- OI 1903
- Country
- HRMY United States
- OI United States
- Employees
- HRMY N/A
- OI N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- OI Containers/Packaging
- Sector
- HRMY Health Care
- OI Consumer Discretionary
- Exchange
- HRMY Nasdaq
- OI Nasdaq
- Market Cap
- HRMY 1.6B
- OI 1.8B
- IPO Year
- HRMY 2020
- OI N/A
- Fundamental
- Price
- HRMY $34.05
- OI $13.44
- Analyst Decision
- HRMY Strong Buy
- OI Buy
- Analyst Count
- HRMY 8
- OI 8
- Target Price
- HRMY $52.88
- OI $15.88
- AVG Volume (30 Days)
- HRMY 701.6K
- OI 1.4M
- Earning Date
- HRMY 05-06-2025
- OI 04-29-2025
- Dividend Yield
- HRMY N/A
- OI N/A
- EPS Growth
- HRMY 13.13
- OI N/A
- EPS
- HRMY 2.62
- OI N/A
- Revenue
- HRMY $744,852,000.00
- OI $6,505,000,000.00
- Revenue This Year
- HRMY $20.06
- OI $1.19
- Revenue Next Year
- HRMY $18.40
- OI $1.15
- P/E Ratio
- HRMY $13.10
- OI N/A
- Revenue Growth
- HRMY 20.62
- OI N/A
- 52 Week Low
- HRMY $26.47
- OI $9.23
- 52 Week High
- HRMY $41.61
- OI $15.72
- Technical
- Relative Strength Index (RSI)
- HRMY 69.53
- OI 69.43
- Support Level
- HRMY $29.82
- OI $12.80
- Resistance Level
- HRMY $30.61
- OI $13.49
- Average True Range (ATR)
- HRMY 1.12
- OI 0.48
- MACD
- HRMY 0.74
- OI 0.16
- Stochastic Oscillator
- HRMY 92.78
- OI 98.08
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.